Keros Therapeutics, Inc. (KROS) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Keros Therapeutics, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
High 11.30 at 11:45 am ET, low 11.14 at 3:30 pm ET.
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
the bull case· 4
4
disclosed supplier and customer ties in SEC filings
sec filingsedgar3
of the funds on file reporting a position in KROS
n-portas of Jun 30 '26+15.47%
change in shares held by the ten largest reporting managers over the latest quarter
13fJun 30 '26131
managers reporting a position in the latest quarterly filings
13fJun 30 '26the bear case· 4
13 of 25
of the largest reporting managers cut their stake in the latest quarter
13fJun 30 '2625
managers whose positions together make up four fifths of the reported value
13fJun 30 '266 of 8
recent reports where the move came in under the options implied range
earnings historyimplied vs realized0.01%
of iShares Russell two thousand ETF assets the largest fund weight on file
n-portJun 30 '26Sides and captions by the model; every figure is ours. Built Sep 16 '26 for the Nov 6 '26 report. Not a forecast, not advice.
Of the 6 companies Keros Therapeutics, Inc. moves with most closely, none share its SEC classification.
Measured against 126 trading days of our own closes. Co-movement, not cause.
SIC 2834, Pharmaceutical Preparations, from each company's own filings. Largest first.
131 managers report a position worth $198.7M between them, and 25 of them hold 80% of it.
tall tick = annual report · 1 on record
KROS (Keros Therapeutics, Inc.) has 1 disclosed suppliers and 3 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.